Adlai Nortye Ltd.
ANLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAdlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. The $727.7M market capitalization puts ANL squarely in small-cap range for its industry. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer.
Market Cap
$727.7M
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-28.61
EPS (TTM)
$-1.11
EPS (Fwd)
$-0.40
ROE
-414.0%
ROA
-42.2%
Cash
$9.0M
Total Debt
$26.4M
Free CF
-$37.7M
52W Change
520.9%
Annual Financials
Cash vs Debt
On the balance sheet, ANL has $9.0M in cash with $26.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$37.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -414.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ANL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.